Novartis Aktie [WKN: 904278 / ISIN: CH0012005267]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Novartis AG

26.04.23		Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients (GlobeNewswire)
25.04.23		Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance (GlobeNewswire)
25.04.23		Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose (GlobeNewswire)
20.04.23		Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis (GlobeNewswire)
03.04.23		Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation (GlobeNewswire)
31.03.23		Novartis Entresto receives positive CHMP opinion for pediatric heart failure (GlobeNewswire)
27.03.23		Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer (GlobeNewswire)
21.03.23		Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (GlobeNewswire)
20.03.23		Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset (GlobeNewswire)
16.03.23		Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer (GlobeNewswire)
09.03.23		Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines (GlobeNewswire)
07.03.23		Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
07.03.23		Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
20.02.23		Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors (GlobeNewswire)
22.11.22		Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH (GlobeNewswire)
07.11.22		New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years (GlobeNewswire)
07.11.22		Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics (GlobeNewswire)
25.10.22		Novartis maintains growth momentum and confirms FY’22 Group guidance (GlobeNewswire)
25.10.22		Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
24.10.22		Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study (GlobeNewswire)
14.10.22		Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer (GlobeNewswire)
22.09.22		Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event (GlobeNewswire)
21.09.22		Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
19.09.22		Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial (GlobeNewswire)
15.09.22		Novartis statement regarding competition authority investigation into assertion of a patent (GlobeNewswire)
10.09.22		Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials (GlobeNewswire)
09.09.22		Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer (GlobeNewswire)
02.09.22		Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses (GlobeNewswire)
01.09.22		Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis (GlobeNewswire)
30.08.22		Novartis presents new data in breast and prostate cancer at ESMO (GlobeNewswire)
25.08.22		Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten (GlobeNewswire)
25.08.22		Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off (GlobeNewswire)
15.08.22		Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer (GlobeNewswire)
25.07.22		Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA (GlobeNewswire)
21.07.22		Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) (GlobeNewswire)
19.07.22		Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance (GlobeNewswire)
19.07.22		Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022 (GlobeNewswire)
30.06.22		New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy (GlobeNewswire)
24.06.22		Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia (GlobeNewswire)
23.06.22		Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments (GlobeNewswire)
23.06.22		Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors (GlobeNewswire)
21.06.22		Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
17.06.22		Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA (GlobeNewswire)
16.06.22		New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity (GlobeNewswire)
12.06.22		Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
12.06.22		Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
07.06.22		Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial (GlobeNewswire)
06.06.22		Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study (GlobeNewswire)
31.05.22		Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 (GlobeNewswire)
28.05.22		FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma (GlobeNewswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Novartis Peer Group Nachrichten

17.01.25		Börse New York: Dow Jones letztendlich im Plus
17.01.25		Gewinne in New York: Dow Jones bewegt sich nachmittags im Plus
17.01.25		Börse New York in Grün: S&P 500 nachmittags stärker
17.01.25		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17.01.25		Starker Wochentag in New York: S&P 500 klettert mittags

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	18.01.2025 20:11
Kaufwert:	EUR
	Hinzufügen Speichern

Novartis Aktie [WKN: 904278 / ISIN: CH0012005267]

Nachrichten zu Novartis AG

Newssuche

Novartis Peer Group Nachrichten

Meistgelesene Nachrichten